Clinical Trial Detail

NCT ID NCT02424617
Title A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors BerGenBio AS
Indications

lung non-small cell carcinoma

Therapies

Bemcentinib + Erlotinib

Age Groups: adult

No variant requirements are available.